ACXP Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	45 828.00
Average Volume	76 950.00
Market Cap	39.77M
EPS	$-282.95 ( 2024-05-15 )
Next earnings date	( $-0.280 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.13
ATR14	$0.0160 (0.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Luci David P	Buy	250 000	Stock Option
2024-02-23	Shawah Robert G.	Buy	145 000	Stock Option
2024-02-23	Deluccia Robert J	Buy	250 000	Stock Option
2024-01-19	Sailer Carl	Buy	19 737	Common Stock
2024-01-19	Sailer Carl	Sell	19 737	Warrants for Common Stock

INSIDER POWER
76.49
Last 61 transactions
Buy: 3 435 791 \| Sell: 229 212

Acurx Pharmaceuticals, Correlation

10 Most Positive Correlations
OZEM	1
DYFI	0.948
BCAN	0.948
RVYL	0.938
MLGO	0.936
FLGT	0.936
SINT	0.934
PRFX	0.933
BNRG	0.932
OCEA	0.932

10 Most Negative Correlations
KINS	-0.922
BAYA	-0.921
CNRLX	-0.92
ISRL	-0.919
DTI	-0.916
ALLT	-0.913
ARYD	-0.91
TAYD	-0.908
FLXS	-0.905
AMZN	-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Acurx Pharmaceuticals, Correlation - Currency/Commodity

-0.48
( neutral )

-0.37
( neutral )

0.00
( neutral )

-0.35
( neutral )

0.16
( neutral )

Acurx Pharmaceuticals, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.150

FY	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.150

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.120

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.490

Financial Reports:

No articles found.

Acurx Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Acurx Pharmaceuticals,

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.